{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:03:05Z","timestamp":1793332985571,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042022kf0056"],"award-info":[{"award-number":["2042022kf0056"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273774"],"award-info":[{"award-number":["82273774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773557"],"award-info":[{"award-number":["81773557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173676"],"award-info":[{"award-number":["82173676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103994"],"award-info":[{"award-number":["82103994"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073690"],"award-info":[{"award-number":["82073690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2020YFA0908800"],"award-info":[{"award-number":["2020YFA0908800"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M672435"],"award-info":[{"award-number":["2020M672435"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019937","name":"State Key Laboratory of Biocatalysis and Enzyme Engineering","doi-asserted-by":"publisher","award":["SKLBEE2021017"],"award-info":[{"award-number":["SKLBEE2021017"]}],"id":[{"id":"10.13039\/501100019937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2020CFA011"],"award-info":[{"award-number":["2020CFA011"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2100300"],"award-info":[{"award-number":["2021YFC2100300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115328","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:19:18Z","timestamp":1680747558000},"page":"115328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Structure-guided identification of novel dual-targeting estrogen receptor \u03b1 degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer"],"prefix":"10.1016","volume":"253","author":[{"given":"Lilan","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rey-Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-063X","authenticated-orcid":false,"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115328_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115328_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115328_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/jehp.jehp_234_19","article-title":"Knowledge of breast cancer risk factors and methods for its early detection among the primary health-care workers in Shimla, Himachal Pradesh","volume":"8","author":"Fotedar","year":"2019","journal-title":"J. Educ. Health Promot."},{"key":"10.1016\/j.ejmech.2023.115328_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdz051","article-title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","volume":"30","author":"Malvezzi","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115328_bib5","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115328_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108350","article-title":"Anticancer or carcinogenic? The role of estrogen receptor \u03b2 in breast cancer progression","volume":"242","author":"Shen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115328_bib7","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115328_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2016.08.008","article-title":"Endocrine treatment in breast cancer: cure, resistance and beyond","volume":"50","author":"Tryfonidis","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2023.115328_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13058-014-0430-x","article-title":"Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase","volume":"16","author":"Fu","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115328_bib10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1071884","article-title":"Connections and regulation of the human estrogen receptor","volume":"296","author":"McDonnell","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115328_bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003495-199856060-00020","article-title":"Letrozole. A review of its use in postmenopausal women with advanced breast cancer","volume":"56","author":"Lamb","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115328_bib12","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm200801h","article-title":"The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the \"core issue\" in the design of estrogen receptor ligands","volume":"54","author":"Katzenellenbogen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115328_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2018.04.009","article-title":"Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen\/aromatase inhibitors","volume":"41","author":"Mills","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115328_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mce.2016.08.011","article-title":"Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER\/EGFR\/ERK\/cyclin D1 pathway: a retrospective study and an in vitro study","volume":"437","author":"Zhang","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2023.115328_bib16","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.5b00760","article-title":"Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer","volume":"58","author":"McDonnell","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib17","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2023.115328_bib18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115328_bib19","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1002\/cncr.32345","article-title":"ESR1 mutations in breast cancer","volume":"125","author":"Dustin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2023.115328_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115328_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115328_bib22","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.25.3752","article-title":"Overcoming endocrine resistance in hormone receptor-positive breast cancer","volume":"25","author":"AlFakeeh","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2023.115328_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","article-title":"Therapeutic ligands antagonize estrogen receptor function by impairing its mobility","volume":"178","author":"Guan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115328_bib24","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1158\/0008-5472.CAN-07-1590","article-title":"Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators","volume":"67","author":"Wittmann","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115328_bib25","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115328_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115328_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bmcl.2013.11.078","article-title":"Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator","volume":"24","author":"Shoda","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115328_bib28","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1021\/acs.jmedchem.6b01468","article-title":"Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ER\u03b1+ breast cancer","volume":"60","author":"Burks","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/acs.jmedchem.6b01917","article-title":"Lead optimization of benzoxepin-type selective estrogen receptor (ER) modulators and downregulators with subtype-specific ER\u03b1 and ER\u03b2 activity","volume":"61","author":"O'Boyle","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.jmedchem.6b01355","article-title":"Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer","volume":"60","author":"Xiong","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsmedchemlett.6b00410","article-title":"Rational design of a boron-modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator","volume":"8","author":"Liu","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115328_bib32","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.bmc.2016.04.068","article-title":"Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator","volume":"24","author":"Shoda","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib33","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1021\/acs.jmedchem.2c00008","article-title":"Discovery of thieno[2,3-e]indazole derivatives as novel oral selective estrogen receptor degraders with highly improved antitumor effect and favorable druggability","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib34","first-page":"118","article-title":"Dual-mechanism estrogen receptor inhibitors","author":"Min","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115328_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.2910560225","article-title":"Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells","volume":"56","author":"Coopman","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115328_bib36","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.1021\/acs.jmedchem.5b00984","volume":"58","author":"De Savi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib37","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib38","first-page":"5","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","author":"Fanning","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2023.115328_bib39","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/cancers11121894","article-title":"The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy","volume":"11","author":"De Santo","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115328_bib40","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-04-2782","article-title":"Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model","volume":"65","author":"Jelovac","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115328_bib41","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib42","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm400467w","article-title":"Histone deacetylase inhibitors equipped with estrogen receptor modulation activity","volume":"56","author":"Gryder","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib43","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1021\/jm400364h","article-title":"Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities","volume":"56","author":"Lv","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib44","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1021\/jm501218e","article-title":"Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities","volume":"58","author":"Lv","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jmedchem.5b01677","article-title":"Synthesis of triphenylethylene bisphenols as aromatase inhibitors that also modulate estrogen receptors","volume":"59","author":"Lv","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib46","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1021\/jm500670d","article-title":"\u03b2-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor\/tubulin ligand","volume":"57","author":"O'Boyle","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib47","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1021\/acs.jmedchem.5b00099","article-title":"Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer","volume":"58","author":"Tang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib48","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.chembiol.2015.10.011","article-title":"Reciprocal regulation of ER\u03b1 and ER\u03b2 stability and activity by diptoindonesin G","volume":"22","author":"Zhao","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115328_bib49","doi-asserted-by":"crossref","first-page":"15063","DOI":"10.1073\/pnas.93.26.15063","article-title":"Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor","volume":"93","author":"Rink","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115328_bib50","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/ja017344p","article-title":"A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells","volume":"124","author":"Mitra","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115328_bib51","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.bmcl.2004.04.064","article-title":"Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents","volume":"14","author":"Sharma","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115328_bib52","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1021\/jm500670d","article-title":"\u03b2-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor\/tubulin ligand","volume":"57","author":"O'Boyle","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib53","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/molecules22091440","article-title":"Novel selective estrogen receptor ligand conjugates incorporating endoxifen-combretastatin and cyclofenil-combretastatin hybrid scaffolds: synthesis and biochemical evaluation","volume":"22","author":"Kelly","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115328_bib54","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm400467w","article-title":"Histone deacetylase inhibitors equipped with estrogen receptor modulation activity","volume":"56","author":"Gryder","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib55","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1021\/acs.jmedchem.5b00099","article-title":"Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer","volume":"58","author":"Tang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib56","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0960-894X(99)00185-7","article-title":"Synthesis and evaluation of geldanamycin-estradiol hybrids","volume":"9","author":"Kuduk","year":"1999","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115328_bib57","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1021\/acs.jmedchem.8b00224","article-title":"Novel hybrid conjugates with dual suppression of estrogenic and inflammatory activities display significantly improved potency against breast cancer","volume":"61","author":"Ning","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113733","article-title":"Balanced dual acting compounds targeting aromatase and estrogen receptor \u03b1 as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer","volume":"224","author":"Caciolla","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib59","doi-asserted-by":"crossref","first-page":"112281","DOI":"10.1016\/j.ejmech.2020.112281","article-title":"Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor \u03b1 (ER\u03b1) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer","volume":"195","author":"He","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib60","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1021\/acs.jmedchem.2c00525","article-title":"Discovery of novel bicyclic phenylselenyl-containing hybrids: an orally bioavailable, potential, and multiacting class of estrogen receptor modulators against endocrine-resistant breast cancer","volume":"65","author":"Deng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nchembio.2236","article-title":"Full antagonism of the estrogen receptor without a prototypical ligand side chain","volume":"13","author":"Srinivasan","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115328_bib62","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/jm020450x","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents","volume":"46","author":"Jordan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib64","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1021\/acs.jmedchem.5b01281","article-title":"Recent progress in the discovery of next generation inhibitors of aromatase from the structure-function perspective","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib65","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1021\/acs.jmedchem.5b00386","article-title":"Discovery and development of the aryl O-sulfamate pharmacophore for oncology and women's health","volume":"58","author":"Thomas","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","article-title":"Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance","volume":"18","author":"Katzenellenbogen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115328_bib68","doi-asserted-by":"crossref","first-page":"72512","DOI":"10.7554\/eLife.72512","article-title":"Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells","volume":"11","author":"Hosfield","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2023.115328_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2019.03.058","article-title":"Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib70","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1021\/jm0506773","article-title":"Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure","volume":"48","author":"Zhou","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115328_bib71","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1021\/acsmedchemlett.9b00591","article-title":"Targeting orthosteric and allosteric pockets of aromatase via dual-mode novel azole inhibitors","volume":"11","author":"Caciolla","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115328_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1087057113502673","article-title":"High-throughput screening assays for estrogen receptor by using coumestrol, a natural fluorescence compound","volume":"19","author":"Wang","year":"2014","journal-title":"J. Biomol. Screen"}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2024.116713","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:07:58Z","timestamp":1778508478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":72,"alternative-id":["S0223523423002945"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115328","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided identification of novel dual-targeting estrogen receptor \u03b1 degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115328"}}